Subcutaneous immunoglobulin (SCIg) is immunoglobulin replacement therapy available to patients with primary and secondary immunodeficiency, as well as chronic inflammatory demyelinating polyneuropathy.
This is a home-based patient self-administered therapy. Patients undergo training with a specialist nurse. SCIg therapy provides patients with treatment-lifestyle flexibility, empowering patients’ autonomy in self-management and improving their quality of life.
Patients must meet one of the following National Blood Authority’s Criteria for the clinical use of immunoglobulin in Australia to be approved for SCIg therapy:
- primary immunodeficiency diseases with antibody deficiency
- specific antibody deficiency
- acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT)
- secondary hypogammaglobulinaemia unrelated to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT)
- Chronic inflammatory demyelinating polyneuropathy (CIDP), (including IgG and IgA paraproteinaemic demyelinating neuropathies)
Please refer to Access to Subcutaneous Immunoglobulin website for more details.
Eligible immunology and neurology patients
Patients can be referred by their treating specialists to SCIg Program Nurse Consultant at 5 West Day Medical Centre.
Haematology referrals should be directed to SCIg Nurse at Day Therapy Unit, Peter MacCallum Cancer Centre.
For more information please contact one of the SCIg specialist nurses.